FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway

JING LIU¹, GUANGBING LI², DEJIE LIU³ and JUN LIU²

¹Department of Ophthalmology, The Second Hospital of Shandong University, Jinan, Shandong 250033; ²Department of Liver Transplantation and Hepatobiliary Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021; ³Department of Anesthesiology, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China

Received September 12, 2013; Accepted January 23, 2014

DOI: 10.3892/mmr.2014.1928

Abstract. Hepatocellular carcinoma (HCC) is a primary cancer of the liver. Target therapy may improve prognosis of HCC. In the present study, we evaluated the inhibition of the Wnt/β-catenin pathway as a potential therapeutic approach. HepG2 cells were treated with the β-catenin inhibitor FH535. β-catenin protein expression was semi-quantitatively assessed using western blot analysis. Cell proliferation was examined with a 3-(4,5-dimethyl-2-yi)‑5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay. The mRNA expression of nitric oxide synthase (iNOS) was detected by reverse transcription polymerase chain reaction. The Griess assay was used to determine nitric oxide (NO) concentration. FH535 inhibited the proliferation of HepG2 cells and decreased β-catenin protein expression. mRNA expression of iNOS, a target gene of the Wnt/β-catenin pathway, was decreased in FH535-treated HepG2 cells compared to the control group. NO production was also reduced by FH535. In conclusion, the β-catenin inhibitor FH535 may inhibit HCC cell proliferation via downregulation of the Wnt/β-catenin pathway. Thus, targeting this pathway may be useful in HCC therapy.

Introduction

Hepatocellular carcinoma (HCC) is a primary cancer of the liver that is predominant in developing countries, with almost 600,000 deaths per year worldwide (1,2). HCC normally develops as a consequence of liver disease and is most often associated with cirrhosis (3). Surgical resection and liver transplantation are currently the best curative options to treat liver cancer (4). However, recurrence or metastasis is common in patients who have had a resection, and the survival rate at 5 years post-operation is 30-40% (5). One of the challenges in modern hepatology is to improve the prognosis of HCC. A few adjuvant therapies have been relatively effective for a number of treatment-naïve or relapsing patients. These therapies include transcatheter arterial chemoembolization, radiofrequency ablation, selective internal radiation therapy and high-intensity focused ultrasound and targeted therapy, and are commonly combined in the clinic (6,7).

The Wnt signaling pathway, originally identified in Drosophila melanogaster, is a highly conserved pathway involved in homeostasis, cell proliferation, differentiation, motility, and apoptosis (8). It is deregulated in a number of cancer types, including HCC (9). In most reported cases, Wnt signaling is activated either by the inactivation of the tumor suppressor gene adenomatous polyposis coli or the mutation of the proto-oncogene β-catenin. This pathway is also involved in HCC arising from HBV/HCV infections and alcoholic liver cirrhosis (10). Upregulation of the Wnt receptor frizzled-7 and dephosphorylation of β-catenin is frequently observed in HCC. Therefore, targeted inactivation of Wnt pathway may be an effective therapeutic approach for cancer. FH535 is a small molecule that can inhibit β-catenin (11).

Nitric oxide (NO) is a diatomic free radical molecule. It is synthesized by the nitric oxide synthase (NOS) (12). There are three isoforms of NOS, the endothelial (eNOS), the neuronal (nNOS) and the inducible NOS (iNOS). A recent study has shown strong in situ co-expression of iNOS and eNOS in ductal carcinomas (13). This study shed light on the role of NO in tumorigenesis. Du et al showed that iNOS is regulated by the Wnt pathway in cancer cells (14).

In the present study, we investigated the effect of FH535 on the proliferation of HepG2 cells. The results from our study showed that the FH535 inhibitor downregulates the expression of β-catenin, thereby reducing the production of NO. Reduced NO levels may underlie reduced proliferation of HepG2 cells.

Materials and methods

Cell culture. The human hepatocellular carcinoma (hepatoma) cell line HepG2 was maintained in Dulbecco's modified...
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 µg/ml penicillin and 100 µg/ml streptomycin. All media and supplements were purchased from Invitrogen (Carlsbad, CA, USA). Cells were maintained at 37°C in a humidified atmosphere with 5% CO₂.

**Protein extraction and immunoblotting.** HepG2 cells were seeded in 6-well plates at 50% confluency and incubated at 37°C overnight. The cells were then treated with phosphate-buffered saline (PBS) or with different concentrations (2, 10 or 20 µg/ml) of HPLC-purified FH535 (Sigma-Aldrich, St. Louis, MO, USA) for 48 h. Cell monolayers were washed twice with PBS and then lysed in RIPA extraction buffer (PBS, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 10 µg/ml phenylmethylsulfonyl fluoride; Millipore, Bedford, MA, USA). Equal amounts of protein (20 µg) were resolved on a sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and western blot analyses were performed using the primary antibodies targeting β-catenin (1:500, cat. no. SC-7963; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and horse-radish peroxidase (HRP)-β-actin (1:10,000, cat. no. A3854; Sigma-Aldrich). Secondary antibodies (anti-mouse, cat. no. SC-2005 and anti-rabbit, cat. no. SC-2004) conjugated with HRP were purchased from Santa Cruz Biotechnology, Inc.

**Cell viability assay.** HepG2 cells were seeded in 96-well plates at a density of 3x10^3 cells/well and incubated overnight at 37°C prior to the addition of a range of FH535 concentrations (1.25-20 µg/ml). The control HepG2 cells were treated with dimethylsulfoxide (DMSO). Cells were further incubated at 37°C in an incubator with a humidified atmosphere and 5% CO₂ for 72 h before cell viability was assessed using the CellTiter-Glo® Luminescent Cell Viability assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Three independent experiments were performed, each in triplicate.

**Cell proliferation assay.** Hepatoma cells were seeded in 96-well plates at 3x10^3 cells/well, maintained overnight at 37°C, and incubated with FH535 at concentrations ranging from 0 to 100 µM. After incubation for 72 h, cell proliferation was monitored using the CellTiter 96® AQueous One Solution Cell Proliferation assay (MTS; Promega) according to the manufacturer’s instructions. Optical density (OD) at 490 nm was measured on a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

**RNA extraction and first strand cDNA synthesis.** AllPrep DNA/RNA Mini kits (Qiagen, Valencia, CA, USA) were used to extract total RNA from HepG2 cells according to the manufacturer’s instructions. Subsequently, a DNA-free™ kit (Applied Biosystems, Carlsbad, CA, USA) was used to remove genomic DNA. To verify the RNA integrity electrophoresis with 5% agarose/formaldehyde/MOPS gels was performed, followed by ethidium bromide staining and visual inspection under UV light. Samples with a 28S:18S rRNA ratio less than 2:1 were excluded. A Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) was used to measure the RNA concentration. RNA purity was investigated by calculating the ratio of absorbance at 260 vs. 280 nm, with a ratio of ~2.0 as the criterion for ‘pure’ RNA. Similar results for the quality and integrity of RNA were observed between the HCC and non-cancerous liver tissue samples. First strand cDNA was synthesized from 1 µg total RNA, using a High Capacity RNA-to-cDNA kit (Applied Biosystems) according to the manufacturer’s instructions. The following conditions were as follows: 37°C for 60 min and 95°C for 5 min. First strand cDNA was stored at -20°C until further analysis.

**Quantitative real-time polymerase chain reaction (qPCR).** qPCR was used to determine the relative levels of iNOS mRNA in FH535-treated and control HepG2 cells, with β-actin used as an internal loading control. An ABI StepOne Plus Real-Time PCR System (Applied Biosystems) was used to perform the qPCR, with the following primers: iNOS, forward, 5’-TCC AAG GTA TCC TGG AGC GA-3’ and reverse, 5’-CAG GGA CGG GAA CTC CTC TA-3’; β-actin, forward, 5’-GGA CTT CGA GCA AGA GAT GG-3’ and reverse, 5’-AGC ACT GTG TTT GCG TAC AG-3’. All samples were run in triplicate. qPCR amplification was conducted using ABI Power SYBR®Green PCR Master Mix (Applied Biosystems) in 20 µl reaction buffer under the
β-actin and expressed as $2^{\Delta\Delta CT}$.

**Results**

**FH535 inhibits the expression of β-catenin.** The effect of FH535 on the expression of β-catenin was examined. FH535 treatment abolished the protein expression of β-catenin (Fig. 1). β-catenin was expressed in the control (DMSO-treated) group.

**FH535 inhibits the proliferation of HepG2 cells.** Basal expression of β-catenin is important for cell proliferation. We thus determined the effect of FH535 on the proliferation of HepG2 cells. FH535 reduced HepG2 cell proliferation rates, as assessed by the MTS assay (Fig. 2).

**NO concentration is reduced following FH535 treatment.** Activation of β-catenin can upregulate iNOSs, and thereby increase the NO concentration. We therefore detected the mRNA expression level of iNOS by reverse transcription polymerase chain reaction (RT-PCR). The results showed that the mRNA of iNOS is decreased following treatment with the β-catenin inhibitor FH535 (Fig. 3A). The Griess assay also showed that the concentration of NO in FH535-treated HepG2 cells is also reduced compared to the control group (Fig. 3B).

**Discussion**

HCC is one of the most frequent and malignant diseases worldwide (7,15). Surgical resection is the treatment of choice at the early stages of HCC (6). However, most HCC patients are in an advanced stage of the disease when diagnosed, and thus do not meet the criteria for surgical treatment. This is one of the reasons for the 5-year survival rate being poor for HCC patients (2,16). The pathophysiology of HCC is not clearly understood, but prognosis of HCC requires understanding of the underlying molecular mechanism. Hepatocarcinogenesis is a complex process associated with accumulation of genetic and epigenetic changes that occur during initiation, promotion, and progression of the disease (17). These cellular events are often accompanied by increased expression of a number of factors that influence the survival of cancer cells by suppressing apoptosis and regulating the cell cycle. Activation of oncogenes and the role of tumor suppressor genes such as the retinoblastoma and p53 genes, have also been well documented (18). The increasing incidence of HCC has led to intense research aiming to elucidate the physiological, cellular and molecular mechanisms of the disease with the ultimate goal of using this knowledge in the development of new treatment strategies.

The Wnt/β-catenin signaling pathway is one of the fundamental pathways directing cell proliferation, cell polarity and cell fate determination during embryonic development and tissue homeostasis (8). β-catenin is a key component of the Wnt/β-catenin signaling pathway (19). Signaling is initiated by the secreted Wnt proteins, which bind to a seven-transmembrane domain receptor encoded by the gene FZD7. Activation of the receptor leads to the phosphorylation of the dishevelled protein, which, through its association with axin, prevents glycogen synthase kinase 3β (GSK3β) from phosphorylating the critical substrate, β-catenin. Unphosphorylated β-catenin escapes recognition by β-TRCP and translocates to the nucleus, where it engages transcription factors such as TCF and LEF to activate the transcription of target genes (20). Abnormal
activation of the Wnt/β-catenin pathway was reported in pancreatic, lung and gastric cancer (21-24).

In addition, the role of the Wnt/β-catenin pathway in liver biology is becoming increasingly evident. The Wnt/β-catenin pathway is an important player in the progression of HCC (9,25). Twenty to 90% of HCCs exhibit β-catenin activation, induced by diverse mechanisms, including mutations in the gene coding for β-catenin. Thus, inhibiting the Wnt/β-catenin pathway may constitute a target therapy for HCC (26). In this study, our results showed that the β-catenin inhibitor can reduce proliferation of the HCC cell line HepG2 via downregulation of β-catenin, and consequently, of its target gene iNOS.

In conclusion, our study has shown that inhibiting the Wnt/β-catenin pathway may reduce the proliferation of an HCC cell line and suggested that the Wnt/β-catenin pathway constitutes a therapeutic target for treatment of HCC.

References